What Does NxGen MDx Screen For?
We screen for up to 120 genetic disorders that can affect your pregnancy, the health of your baby, and your family's future. You can learn more about our various screens — and which sets of screens (or "panels") align with where you are in your reproductive journey.
Fanconi Anemia Type C
What Your Test Results Mean:
There is preliminary evidence suggesting that carriers of Fanconi anemia type C may have a higher chance of developing cancer, but the evidence is currently limited. You and your partner or donor would both have to be carriers of Fanconi anemia type C for there to be an increased chance to have a child with symptoms; this is known as autosomal recessive inheritance. Carrier testing of your partner or donor is recommended in addition to consultation with a genetic counselor for a more detailed risk assessment.
We recommend that you share this information with all of your health care providers. Since this is an inherited gene change, this information may be helpful to share with family members as it may impact their family planning.
Fanconi anemia type C is an inherited disorder characterized by a range of physical abnormalities, progressive bone marrow failure, and an increased risk of cancer. Physical abnormalities, found in 75% of cases, are typically present at birth and include short stature, upper limb abnormalities, and hyperpigmentation of the skin. The hematologic complications of Fanconi anemia type C typically develop within the first decade of life and are highly variable. Cancer risk remains a concern throughout the lifespan. Individuals with Fanconi anemia type C are not able to properly repair DNA damage, leading to premature cell death or uncontrolled cell growth.
Prognosis is generally unfavorable. Due to the physical abnormalities, bone marrow failure, and increased risk for cancer, affected individuals typically die before the age of 30.
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Fanconi anemia, but the high risk for solid tumors remains and may even be increased in those undergoing HSCT. Surveillance for early detection and surgical removal remain the mainstay of treatment for solid tumors. Oral androgens improve blood cell counts (red cell, white cell, and platelets) in many individuals.
Talk to a Genetic Counselor
As a NxGen client, you'll have access to personal genetic counselors who can help explain the results of your screens and provide insight on how to move forward. To schedule a personal conference to discuss your screen results, call (855) 776-9436. or click the link below.Discuss Your Screening Results